Affinivax snags $226m Series C
Affinivax Inc, a clinical-stage biopharmaceutical company, has raised $226 million in Series C financing.
Affinivax Inc, a clinical-stage biopharmaceutical company, has raised $226 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination
